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Lapsuusiän kasvuun vaikuttavat sekä perintötekijät että ympäristötekijät. Ensimmäisen puolen 
vuoden aikana ravitsemus on voimakkaimmin lapsen kasvua säätelevä tekijä. Ravitsemustila 
vaikuttaa insuliinin kaltaisen kasvutekijä 1:n (IGF-1) pitoisuuksiin, joka osallistuu yhdessä 
kasvuhormonin kanssa kasvun säätelyyn. Matalan tulotason maissa lasten vajaaravitsemus on 
yleistä, minkä seurauksena lasten IGF-1-pitoisuudet ovat matalia. IGF-1-pitoisuuksiin vaikuttavat 
lisäksi ympäristöperäinen suoliston toimintahäiriö, hygieniataso sekä äidin biologiset 
ominaisuudet.  
 
Suurin osa IGF-1-molekyyleistä kulkee verenkierrossa kiinnittyneenä sitojaproteiini 3:een (IGFBP-
3), joka osallistuu biologisesti aktiivisen IGF-1:n säätelyyn. Tutkimuksessa selvitettiin plasman IGF-
1- ja IGFBP-3-pitoisuuksien jakaumaa ja siihen vaikuttavia tekijöitä 6, 18 ja 30 kuukauden ikäisillä 
maaseudulla asuvilla malawilaislapsilla. Plasmanäytteet on kerätty vuosina 2011–2015 osana 
äitien ja lasten ravitsemustutkimusta.  
 
IGF-1- ja IGFBP-3 -pitoisuudet analysoitiin fluoresoiviin väriaineisiin perustuvalla Luminex XMap –
tekniikalla. IGF-1-pitoisuuksien keskiarvo 6 kuukauden iässä oli 13,1 ng/ml (n = 519); 18 kuukauden 
iässä 12,5 ng/ml (n = 605) ja 30 kuukauden iässä 14,5 ng/ml (n = 581). IGFBP-3-pitoisuuksien 
keskiarvot olivat vastaavasti 2643ng/ml (n = 474); 2676 ng/ml (n = 584) ja 2652 ng/ml (n = 580). 18 
ja 30 kuukauden iässä IGF-1- ja IGFBP-3 -pitoisuuksien keskiarvot olivat tytöillä suuremmat kuin 
pojilla. IGF-1- ja IGFBP-3 -pitoisuudet korreloivat keskenään kaikissa ikäryhmissä. Äidin pituus 
korreloi lasten IGF-1- ja IGFBP-3 -pitoisuuksiin, mutta äidin painoindeksi, ikä, tulehdusparametrit ja 
kotitalouden varallisuus korreloivat tuloksiin vain osittain tai eivät lainkaan. Kuivakaudella 
plasmanäytteiden IGF-1- ja IGFBP-3 -pitoisuudet olivat useimmiten korkeammat kuin 
sadekaudella. Asuinpaikkakunta, juomaveden lähde ja käytettävissä olevat saniteettitilat 
vaikuttivat tuloksiin muutamissa vertailluissa ryhmissä. Jotta IGF-1- ja IGFBP-3 -pitoisuuksia 
voitaisiin hyödyntää sairauksien diagnostiikassa, tulisi käyttää vertailukelpoisesta tutkimusjoukosta 
saatuja viitearvoja sekä samanlaisia laboratoriomenetelmiä.   
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1. BACKGROUND 
 
1.1 Malnutrition among children 
Definition 
Terms malnutrition and undernutrition are often used to describe the same phenomenon (1) but 
term malnutrition refers to deficiencies, excesses, or imbalances in a person’s intake of energy 
and/or nutrients. Forms of undernutrition are stunting, wasting, underweight and micronutrient 
deficiencies. (2) Undernutrition is defined as a state in which the amount of energy and nutrients 
from food is inadequate to meet nutritional demands of a subject (1). Stunting is defined as 
children’s height-for-age more than two standard deviations (SD) below the WHO Child Growth 
Standards median. Likewise, wasting and underweight are defined as children’s weight-for-height 
and weight-for-age more than two SD below the WHO Child Growth Standards median. (3) 
Micronutrient insufficiencies indicate a person has deficiencies in vitamins and minerals (2). 
 
Prevalence 
Undernutrition is a huge problem in low- and middle-income countries and especially in sub-
Saharan Africa (4). About one third of children in developing countries suffer from stunting (5). In a 
meta-analysis which included 32 Sub-Saharan countries, the prevalence of stunting was 33.2%, the 
prevalence of wasting was 7.1% and the prevalence of underweight was 16.3% among children 
younger than five years (4).  According to Unicef’s statistics 42.4 % of Malawian children were 
stunted and 16.7% were underweight in 2013 - 14 (6). In rural Malawi incidence numbers among 0 
– 36 months old children are higher: 70 % of children were stunted and 40 % were underweight 
(7). In the meta-analysis it was shown that prevalence of stunting is 47.1 % in Malawi. This was the 
second highest stunting percentage of the African countries that were included in the meta-
analysis. (4) 
 
Adverse outcomes 
Adverse outcomes of malnutrition is a combination of many factors which can occur 
simultaneously, such as inadequate diet intake, recurrent infections, micronutrient deficiency and 
low income. All these factors negatively affect child growth. Take stunting as example, mortality 
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and morbidity due to infections, such as pneumonia and diarrhea, are higher in stunted children 
compared to well-nourished children. (8) Brain development is negatively affected (4) which leads 
to lower cognitive capacity. Development of motor skills and school attendance are poorer in 
stunted children (8).  
Stunting in childhood has consequences for life in adulthood: economic status is lower and in 
some cases the risk of overweight, hypertension and cardio-vascular diseases is higher. The risk of 
having metabolic syndrome in adulthood has been explained by epigenetic changes in metabolism 
due to lack of nutrition prenatally and in early childhood. (8)  
 
 
1.2 Child growth 
Normal growth 
The growth after birth can be divided into three phases according to the infancy-childhood-
puberty (ICP) model: 1) the growth during infancy, 2) childhood and 3) puberty. During infancy the 
growth velocity is high: infants grow about 25 cm during the first 12 months of life. The growth of 
infancy continues up to first 2 – 3 years of life but the velocity is more modest. Childhood growth 
begins during 6 – 18 months of age which means that infancy and childhood growth phases occur 
simultaneously. Thus, the two phases cannot be clearly separated from each other. During puberty 
the growth velocity increases again: girls have the peak growth velocity at age of 12.1 years and 
boys at age of 14.1 years. (9) 
During the first couple of months of life exclusive breastfeeding (EBF) has a positive effect on 
growth velocity. Growth hormone (GH) is needed already during infancy growth but the role of GH 
becomes more important later.  After infancy the most important regulator of child growth is 
growth hormone – insulin-like growth factor 1 (IGF-1) system. (9) At the age of 6 – 12 months the 
role of GH in IGF-1 production becomes more important than nutrition. (10) Some hormones, such 
as thyroid hormones and sex steroids, affect growth plates in cartilage but these hormones have 
also important role in modulation of GH – IGF-1 –system. (9, 11) Thyroid hormone is needed for 
growth throughout the period of growing (9). 
Growth hormone releasing hormone (GHRH) and growth hormone inhibitory hormone, called 
somatostatin, are produced and released by the hypothalamus. These hormones affect the 
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anterior pituitary gland: GHRH stimulates excretion of growth hormone and somatostatin inhibits 
the process. GH is released in pulsatile pattern. The regulation of GH release is based on negative 
feedback system: when the amount of GH is high in bloodstream the release of GHRH is 
diminished. This causes levels of GH diminish too. (12) 
 
IGF-1 in normal growth and factors regulating IGF-1 concentration  
Most functions of GH are mediated via IGF-1. IGF-1 production is stimulated when GH binding 
receptors are activated in the target organs. One of the target organs is the liver. IGF-1 produced 
by the liver is excreted in the circulation and this circulating IGF-1 functions as a hormone. IGF-1 
stimulates cartilage of long bones to grow in length. (9, 11) The regulation of IGF-1 production is 
also based on negative feedback system: increased concentration of IGF-1 suppresses production 
of GH which in turn slows down IGF-1 production in the target organs (13). IGF-1 is also an 
independent growth factor affecting cell proliferation and differentiation and preventing 
apoptosis (14). 
IGF-1 production is regulated by several factors, for example growth hormone concentrations, 
age, pubertal status, liver function, and nutritional status (15, 16). At birth the IGF-1 concentration 
is relatively low but it increases during childhood. By the beginning of puberty and at the end of 
puberty the IGF-1 concentrations are on the same levels as during adulthood. During a few years 
of puberty the concentrations are 2 – 3  times higher than in adults. (11) IGF-1 is produced by the 
liver so liver function affects IGF-1 concentration (16).  
 
The role of nutrition in IGF-1 concentration 
IGF-1 concentrations are lower in malnourished subjects compared to well nourished subjects: 
IGF-1 concentrations are lower in people with significant energy or protein deficiency. It has been 
studied that amount of nutrition affects IGF-1 concentrations also within normal IGF-1 range. (13) 
The quality of nutrition may also affect IGF-1 concentrations: formula fed infants had higher IGF-1 
concentrations at ages of 3, 6 and 12 months compared to breastfed infants. The reasons for this 
difference are not clear: faster weight gain or larger amount of adipose tissue in formula fed 
infants are some possible explanations. (17) Milk feeding practices may also affect the 
concentration of biologically available IGF-1. This has been suggested since there have been no 
differences in IGF binding protein 3 concentrations in formula fed and breastfed infants. (10) It is 
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also possible that IGF-1 production is increased by higher protein intake (18). It is not known if the 
total protein intake or the amount of essential amino acids are more significant for IGF-1 
production (13).  The role of protein may be important for growth among malnourished children: 
it has been suggested that GH stimulation in malnourished subjects is more dependent on amount 
of dietary protein than total amount of energy (13).  
It has been studied that low IGF-1 concentrations in stunted 1 year old children might be caused 
by suboptimal nutrition. Besides protein and amino acids, also the amount of carbohydrates in 
diet affect IGF-1 concentrations. If carbohydrate-rich foods were the main source of energy, the 
amount of vegetables and protein, such as dairy products, were low. Thus, the quality of diet was 
suboptimal. The role of fat in diet should be also taken into account: It has been suggested that 
low amount of fat in diet leads to deficiency of essential fatty acids. Also in this case, the quality of 
nutrition is poor which might lead to stunting and low IGF-1 concentrations. In addition, some 
minerals such as zinc, potassium, calcium, and magnesium concentrations correlate positively with 
IGF-1 concentrations. (13)   
 
Other factors affecting child growth 
Environmental factors have a huge impact on a child’s growth during the first two years of life. 
These factors include frequent infections, maternal characteristics such as nutritional status, 
availability of health care services, feeding practices, hygiene and sanitation. (8) 
 
Infections 
Infections affect the regulation of IGF-1 –axis. IGF-1 production by the liver is suppressed during 
intercurrent infections (e.g. pneumonia, diarrhea) and during chronic inflammatory diseases (e.g. 
Crohn’s disease, juvenile idiopathic arthritis).  Suppressed IGF-1 production caused by frequent 
infections can deteriorate child’s growth. There are also other mechanisms that affect growth 
during infections, for example anorexia, increased nutrition demand, malabsorption, and 
catabolism. Acute-phase reactions also suppress nutrients transport from the bowel to other 
tissues. Pro-inflammatory cytokine concentrations and other markers of immune activation 
increase during infections while IGF-1 concentrations decrease, (19) though the correlation is not 
always consistent (20).  
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Recurrent infections can be one cause for growth problems. On the other hand, it has been 
studied that malnourished children have more infections compared to well-nourished children. 
Infections among malnourished children are more frequent, more severe and longer-lasting. 
However, causes and consequences of infections and impaired growth have not been confirmed. 
(8) 
Diarrhea is a common infection in childhood. About 25 % of stunted children in developing 
countries had had at least five episodes of diarrhea by age of 24 months. It is not clear whether 
diarrhea causes stunting or not. (8) It is common that after diarrhea and other infections children 
have a time period of faster growing, so called catch-up growth (15). Thus, evaluating 
consequences of diarrhea is difficult. On the other hand, it has been noticed that children with 
typical diarrheal burden were 0.38 cm shorter at age of 2 years compared to children without 
diarrhea. (8) 
 
Maternal characteristics 
Characteristics of a mother affect intrauterine growth of a child: placental development, maternal 
nutritional status and endocrine and metabolic signals have been proven to affect a child’s growth.  
Thus, stunting can begin already before birth. It has been estimated that stunting has begun 
during antenatal period in about 20 % of stunted children. If a mother is stunted herself or is 
affected by malnutrition there is a higher risk that a child will be stunted as well. The risk of 
mortality and problems with pregnancy are more common in children of stunted mothers. 
Children of stunted mothers are more often small for gestational age (SGA). Those born preterm 
(before 37th week of pregnancy) and SGA are higher risk for poor growth and mortality. Mortality, 
underweight and stunting during infancy and childhood are negatively associated with maternal 
height. (8) 
There might be common factors that affect growth pre- and antenatally but these factors are not 
clearly known yet. One proposed mechanism is inflammation: mothers with high inflammatory 
markers, such as C-reactive protein (CRP), had more often stunted infants compared to mothers 
who had normal levels of CRP. Thus, inflammation might be a link between prenatal and antenatal 
stunting. (8) Alpha-1 acid glycoprotein (AGP) is another inflammatory marker which rises in 
response to inflammatory process in the body (21). AGP levels rise slower and stay elevated longer 
compared to CRP levels (5). 
 6 
 
Feeding practices  
Exclusive breastfeeding (EBF) has been proven to decrease mortality and morbidity. In addition, 
EBF improves cognitive capacity but the effect for growth is not clear. It has been considered that 
the role of EBF is not significant if growth failure has begun prenatally and continues during the 
first six months of life. (8) 
 
Socioeconomic status 
Stunting is also associated with low socioeconomic status: inadequate food intake is the main 
reason for poor growth in communities where people have low socioeconomic status. Changes is 
socioeconomic factors have an impact on child’s growth. It has been noticed improvement in 
linear growth during economic development in China and growth is improved among those who 
move from a country with low socio-economic status to a country with better socio-economic 
conditions. (8) 
 
Water, sanitation and hygiene 
Water, sanitation and hygiene (WASH) have a huge impact on child’s health. It has been suggested 
that poor WASH conditions might be reason for childhood underweight due to diarrhea and 
undernutrition. It has been proven in several studies that improvement in water supply and 
sanitation leads to better growth in childhood. (22) However, there is also a study showing that 
improved WASH conditions alone did not improve child growth. But when improvement in WASH 
conditions was combined with nutrition counselling there was a positive effect on child linear 
growth in rural Bangladesh. (23) 
 
 
1.3 Environmental enteric dysfunction 
Introduction 
Many factors can cause undernutrition, e.g. inadequate food intake, frequent infections and 
inflammation in gastrointestinal tract (24). Recently, environmental enteric dysfunction (EED) has 
been shown to be associated with growth failure in low-income settings. EED is an inflammatory 
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condition in which the permeability of the small intestine increases and the absorption of 
nutrients is deteriorated. EED and stunting among infants and children are strongly connected but 
the causality of EED and stunting is not clear. It has been suggested that infections and 
malnutrition might be reasons for EED but probably the condition is multifactorial. Some other 
proposed reasons for EED are nutritional deficiency (vitamin A, zinc) and micro-organisms. EED is 
more common in low- and middle-income countries than in high-income countries. (25) 
 
The small intestine physiology 
The small intestine is the major site of absorption of nutrients. The area of absorption in the small 
intestine is increased because of three anatomical features: 1) the small intestine wall is folded, 2) 
there are villi (length of 1 mm) on the surfaces of the folds and 3) there are microvilli on the 
surfaces of villi. Thus, the total area of absorption in the small intestine is large. The small intestine 
also secretes enzymes that are needed for complete digestion. When digestion is completed 
nutrients are transported from the lumen of the small intestine. Finally nutrients end up into 
bloodstream and are delivered to various body parts where nutrients can be utilized. Besides 
nutrients, also water and ions are absorbed in the small intestine. (26) 
Moreover, the small intestine has an important role in the local immune response. The small 
intestine protects body from harmful antigens that are in the contents of the small intestine.  The 
normal bacterial flora of the small intestine and the mucosal lining protect the body from harmful 
agents in the gut lumen. There are lymphatic cells that are activated by pathogens in the small 
intestine. There are also antibacterial agents secreted by the crypts around the villi. The epithelial 
cells in the small intestine lumen are tightly connected to each other which prevents crossing of 
harmful agents from the lumen to the other parts of the body. (26) 
 
Pathophysiology of EED 
There are six aspects in the pathophysiology of EED that should be taken into account: 1) gut 
permeability, 2) microbial translocation, 3) systemic inflammation, 4) gut inflammation, 5) 
dysbiosis, and 6) nutrient malabsorption. The permeability of small bowel is increased in EED so 
the bowel becomes more permeable for large particles such as intestinal bacteria and microbial-
associated macromolecules that move to the systemic circulation. The particles can activate the 
immune system which leads to systemic inflammation. Inflammation is present also locally in the 
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small bowel. Another typical feature of EED is diffuse villous atrophy. This decreases area of 
absorption in the small bowel which leads to nutrient malabsorption. Malabsorption and 
inflammation can lead to impaired growth. (24) 
 
EED and growth failure 
Consequences of EED are individual: someone can have mild malabsorption and major bacterial 
translocation in the gut while someone else can have severe malabsorption but only minor 
bacterial translocation (24). When the absorption of nutrients is deteriorated the risk of 
malnutrition is increased (25). Consequences of deteriorated nutrient absorption can be clinically 
significant in childhood when growth velocity and nutrient demand are high (8). EED causes 
inflammation which deteriorates linear growth and therefore can lead to stunting (24). Chronic 
inflammation itself may also be one reason for stunting (5). Even though EED is associated with 
stunting it has been difficult to prove causality between these conditions (27).   
 
Methods and biomarkers in diagnosing EED 
The nature of EED is still unclear because the condition is multifactorial and there is no simple way 
to diagnose EED. Some invasive methods have been used, such as endoscopies.  These are not 
easily accessible and they cause discomfort for a patient so it has been considered that there 
should be a non-invasive point-of-care method for diagnosing EED. (24, 27, 28) There is currently 
no gold-standard method or biomarker to diagnose EED (27), making studies challenging. The 
requirements for it are that it should be affordable, simple and practical (27). So far, the most 
common non-invasive method is lactulose:mannitol test which is based on absorption of two 
sugars: non-absorptive disaccharide lactulose and transcellularly absorptive monosaccharide 
mannitol are administered orally. These sugars are secreted mostly unmetabolized and excreted 
by the kidneys.  Thus, it is possible to measure amounts of lactulose and mannitol in the urine and 
compare results to the oral dose to assess the gut permeability. The result is called 
lactulose:mannitol ratio (L:M ratio). If the amount of lactulose in the urine is elevated it can be 
assumed that the small intestine permeability is increased. (24, 27, 28) 
Some fecal biomarkers have been tested, for example calprotectin and lactoferrin. The problem is 
that the tested fecal biomarkers indicate an inflammatory process in the gastrointestinal tract but 
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the biomarkers are not specific for EED. (24) In addition, it has been suggested that breastfeeding 
might affect the concentrations of calprotectin and lactoferrin in infants. Another problem is that 
there are no reliable reference values for these biomarkers in children. (27) 
In addition, some serum biomarkers have also been tested for EED diagnosis, eg. interleukin 6 (IL-
6), C-reactive protein (CRP), lipopolysaccharide, ferritin, and IGF-1 (24). IGF-1 could be evaluated 
in the assessment of growth since linear growth is diminished by systemic inflammation and EED. 
It has been also suggested that IGF-1 could be one of the biomarkers in monitoring EED, though 
there was no clear correlation between L:M ratio and IGF-1 concentration. (27) Measuring IGF-1 
concentrations could be used in monitoring and diagnosing EED if this method is improved and 
validated in the future. 
 
Prevention of stunting caused by EED 
One possible intervention to prevent stunting caused by EED is zinc supplementation. Zinc 
deficiency might affect villous function decreasing villous surface area and absorptive capacity in 
the gastrointestinal tract. In addition, zinc deficiency can reduce appetite. Thus, zinc 
supplementation could be one possible intervention to prevent harmful factors that play a role in 
the development of EED.  Other possible interventions include access to clean drinking water and 
building and using of toilets. In addition, breastfeeding is an intervention: exclusive breastfeeding 
is recommended during the first six months of life, and breastmilk could be used as a part of 
nutrition for children who are older than six months (24). 
 
EED and IGF-1 
EED is a low-grade chronic inflammatory condition, which suppresses IGF-1 production (5). The 
mechanism of deteriorated growth in EED is mediated via cytokine interleukin 6 (IL-6), which 
decreases production of IGF-1 and inhibits its effect on growth plates accordingly. Thus, linear 
growth is diminished. (24) It has been reported that Zimbabwean infants with EED were stunted, 
had low IGF-1 concentrations, and high cytokine concentrations (25). Prendergast et al. found that 
low IGF-1 concentrations and stunting were associated with high inflammatory markers in blood, 
but no evidence about association between gut permeability and stunting was found (5).  
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1.4 Insulin-like growth factor 1 
IGF-1 is a peptide hormone produced mainly by the liver hepatocytes (16). Other tissues, such as 
the brain, muscle, and bone are also able to produce IGF-1 (29). IGF-1 consists of 70 amino acids 
and it has four chains: A, B, C, and D. A and B chains are similar with insulin, a hormone produced 
by the beta cells of pancreas, but C and D chains are not present in insulin molecule (16). IGF-1 and 
insulin have many similar effects on growth (12). The structure of IGF-1 receptors and insulin 
receptors are similar but ligand affinity is different (30). IGF-1 can act as a local paracrine hormone 
or as a systemic hormone. Other growth factors lack this feature. (29) IGF-1 stimulates cell 
proliferation and differentiation and protects cell from apoptosis. Effects of IGF-1 are mediated via 
IGF-1 receptors which are present in all tissues. (14) 
IGF-1 deficiency or dysfunction is associated with growth failure (15). IGF-1 concentration analysis 
can be used to evaluate hormonal growth regulation and possible problems with GH – IGF-1 axis 
(16). Fluctuation of GH concentration due to its pulsatile release makes it difficult to measure. IGF-
1 concentrations are more stable. (12) Therefore, measuring IGF-1 concentrations is more 
practical than measuring GH concentrations.  
 
 
1.5 IGF binding protein 3 
Insulin-like growth factor binding proteins (IGFBP) have three functions: they are carrier proteins 
that transport IGF-1 to target cells, affect interaction of IGF-1 and their receptors and prolong half-
time of IGF-1 (11). There are 6 different binding proteins for IGF-1, from IGFBP-1 to IGFBP-6 (29). 
The amount of IGFBP-3 is the most significant (11). About 90 % of IGF-1 is attached to IGFBP-3 
(13). IGF-1 and IGFBP-3 form a complex with an acid-labile subunit. IGF-1 is stored in the blood 
stream when attached to the complex: the complex can regulate the amount of biologically 
available IGF-1 by releasing IGF-1 molecules when needed. (29, 31) IGF-1 molecules are more 
tightly bound to their carrier proteins than to their receptors. When IGFBPs and IGF-1 are attached 
the amount of free IGF-1 is decreased. Half-time of IGF-1 alone is 10 minutes but attachment to 
IGFBP-3 and acid-labile subunit makes the half-time to about 12 – 15 hours. IGFBP-3 
concentrations are increased when growth hormone or IGF-1 concentration is increased. Thus, 
lack of growth hormone decreases IGFBP-3 concentration.   
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Nutritional intake is the most important regulator of all IGFBPs. Concentrations of IGFBP-3 remain 
relatively stable during the day (11, 13, 32). Besides nutrition status, IGFBP-3 concentration also 
depends on age like IGF-1. They both increase with age reaching the highest values at puberty and 
decrease after that (31). IGFBP-3 concentration can also be used as an indicator of GH – IGF-1 –
axis among infants. Evaluation of GH – IGF-1 –axis becomes more accurate if both IGFBP-3 and 
IGF-1 are measured. On the other hand, if it is only possible to measure one of the indicators, it 
has been suggested that IGFBP-3 should be measured among those who are younger than two 
years and IGF-1 should be used among the older children. (16) 
 
 
1.6 IGF-1 and IGFBP-3 concentrations in previous studies 
IGF-1 and IGFBP-3 concentrations among infants and children have been reported in some 
previous studies. The summary of these studies is presented in Table 1. The reference values for 0 
– 6 years old Turkish children were established by Yüksel et al (31). Bidlingmaier et al. studied IGF-
1 concentrations at different age groups from birth to senescence (33). Bedogni et al. used 
chemiluminescence assay method to establish reference values for IGF-1 concentrations among 0 
– 18 years old Italian children and adolescents. (34) Löfqvist et al. used samples from 1.1 – 18.3 
years old Swedish subjects to establish reference values for IGF-1 (35). Jones et al. studied acute 
illness and suppression of growth hormone axis in 6 weeks to 18 months Zimbabwean children 
(19). There were also studies from Korea (36), India (37), Burkina Faso (38) and United States (39). 
The IGF-1 and IGFBP-3 concentrations are shown in Table 1 for children between 0-3 years old if 
the data is available. 
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Table 1. Summary of IGF-1 and IGFBP-3 concentrations and laboratory methods used in some previous studies. 
Authors 
(reference) 
Publication 
year 
Country of 
subjects 
Age of 
subjects 
Main results about IGF-1 
and IGFBP-3 
concentrations 
IGF-1 
concentrations 
(converted to 
ng/ml) among  
< 3 years old 
children*  
IGFBP-3 
concentrations 
(converted to 
ng/ml) 
Laboratory method 
Bedogni et 
al. (34) 
2012 Italy 0 – 18 
years 
Increase with age. Sex 
affects the results less 
than age. 
25 – 252 ** 
 
 Chemiluminescence assay 
Bidlingmaier 
et al. (33) 
2014 United States, 
Canada, Europe 
(Austria, 
Denmark, 
Germany, 
Sweden) 
0 – 94 
years 
Low during the first year 
of life, then gradually 
increase and reach the 
highest values during 
puberty at age of 15. 
17.9 – 164.2 
among females, 
27.0 – 204.5 
among males ** 
 
 Automated 
chemiluminescent 
immunoassay (IDS-iSYS; 
Immunodiagnostic Systems) 
Brabant et al. 
(40) 
2003 Germany, 
Belgium, 
Sweden 
1 month 
– 88 
years 
Depend on age, the 
highest values among 14-
year-old girls and 16 year-
old-boys. 
13 – 159 **  Chemiluminescent 
immunoassay  (Nichols 
Advantage®; Nichols 
Institute Diagnostics, San 
Clemente, Calif., USA) 
Chaler et al. 
(41) 
2009 Argentina, Italy 0 – 18 
years 
Increase from early 
childhood to puberty. 
Higher levels among girls 
compared to boys. IGFBP-
3 levels increase from 
early childhood to 
puberty.  
38.5 – 151.0 ** 2.32 – 2.82 ** Chemiluminescent assay 
Hyun et al. 
(36) 
2012 Korea 0 -17 
years 
IGF-1 and IGFBP-3 
concentrations increase 
with age among 
prepubertal children and 
decrease after that. 
not available **  Immunoradiometric assay 
(IRMA, Immunotech) 
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Jones et al. 
(19) 
2015 Zimbabwe 6 weeks 
– 18 
months 
Lower among children 
with recent acute illness. 
around 20 – 60 
(estimation)  
 ELISA (R&D Systems) 
Kouanda et 
al. (38) 
2008 Burkina Faso 0 – 5 
years 
Decrease from birth to 24 
months, increase after 
that. 
27 – 45 (from < 5 
months of age to 
5-year-old 
children) ** 
 Filter paper, 
radioimmunoassay, 
chromatography 
Löfqvist et al. 
(35) 
2001 Sweden 1.1 – 
18.3 
years 
Increase with age among 
prepubertal and early 
pubertal children. 
Difference between boys 
and girls during puberty.  
around 0.05 – 0.1 
(estimation) ** 
 Radioimmunoassay 
(Mediagnost GmbH, 
Tübingen, Germany) 
Soldin et al. 
(39) 
2008 United States 0 – 18 
years 
IGF-1 and IGFBP-3 
concentrations increase 
with age, the highest 
values during puberty. 
30 – 174 
(reference 
intervals) ** 
1300 – 3500 
(reference 
intervals) ** 
Chemiluminescent 
immunometric methods 
(IMMULITE 2000®) 
Wiley et al. 
(37) 
2018 India 0 – 2 
years 
Positive association with 
height at 2 years of age 
and milk intake. 
mean 49.4 at age 
of 2 years 
mean 1953.8 at 
age of 2 years 
not available 
Yüksel et al. 
(31) 
2011 Turkey 0 – 6 
years 
IGF-1 and IGFBP-3 
concentrations increase 
with age. 
0.408 – 1. 609 ** 53.30 – 73.38 ** ELISA kits 
* The results shown in this column represent the participants who were younger than 3 years old even though some studies included also older participants. 
** The study includes also participants older than 3 years old.  
Estimation: The numerical values shown here are estimated from graphs. 
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2. MATERIALS AND METHODS 
 
2.1 Objectives  
The purpose of this study was to analyze distribution of plasma IGF-1 and IGFBP-3 concentrations 
among 6- to 30-month-old rural Malawian children. The results were compared to previous 
studies of IGF-1 and IGFBP-3 concentrations carried out by other research groups with different 
laboratory methods and children with different ages and ethnicity. The distribution of IGF-1 and 
IGFBP-3 concentrations were analyzed in three different age groups (6, 18 and 30 months) to see 
how concentrations vary within age. The study also assessed if maternal/child characteristics and 
environmental factors affect IGF-1 and IGFBP-3 concentrations. Maternal/child characteristics 
included maternal age, height, BMI, CRP, AGP and child gender. Environmental factors included 
household wealth, season, site of sample collection, source of drinking water and sanitation 
facility.  
 
2.2 Study site and study population 
This study is a sub-study using data and plasma samples that were collected from a randomized, 
partially blinded, parallel group controlled trial iLiNS-DYAD (International Lipid-Based Nutrient 
Supplements, mother-child dyads) in rural Malawi. 1391 pregnant women were enrolled. The 
purpose of the project was to determine how stunting among children could be prevented by 
using lipid-based nutrient supplements for a mother during pregnancy and lactation and for a 
baby during infancy. (42) 
Enrollment of pregnant women happened at three public antenatal clinics before 20th week of 
pregnancy. Attendance percentage of antenatal clinic visits in rural Malawi is very high so it can be 
assumed that the study population of children represents typical rural Malawian children well. 
(43) The study site consists of the catchment areas of three health centres in Lungwena, Malindi 
and Mangochi, Mangochi district, Southern Malawi (44).  
781 live-born Malawian children participated a follow-up from birth to 2.5 years of age. The blood 
samples were collected from children during three separate follow-up visits at the clinics. The 
samples were not available at each visit from every participant. (43) Valid IGF-1 concentration 
results were available from 1705 samples and valid IGFBP-3 concentration results were available 
from 1638 samples.  
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2.3 Data collection 
The whole blood samples were collected at the study clinics and centrifuged at 3,000 RPM for 15 
minutes and separated plasma was aliquoted into storage cryovials. The samples were first put at -
20 °C freezers within 1 – 4 hours from sample collection. They were transported to -80 °C freezers 
within 48 hours. The samples were shipped with dry ice to Finland where laboratory analyses of 
IGF-1 and IGFBP-3 were performed.  The samples were thawed and centrifuged prior to laboratory 
analyses. (43) 
Information of maternal characteristics and environmental factors were collected with data 
collection forms during maternal enrollment and follow-up visits at the study clinics by trained 
professionals. Maternal height and weight were measured and biological samples were taken at 
the clinics. 
 
2.4 Laboratory analyses 
IGF-1 concentrations of the stored plasma samples were analyzed with MILLIPLEX® MAP HIGF-1, II 
Magnetic Bead Panel Kit. IGFBP-3 concentrations were analyzed with MILLIPLEX® MAP Human IGF 
Binding Magnetic Bead Panel kit. These are commercial kits by EMD Millipore (Merck Life Science 
Oy). The analysis was based on the LUMINEX xMAP® technology. (45) 
 
Laboratory analyses of IGF-1  
Frozen plasma samples were thawed completely at room temperature, then followed by vortexing 
and centrifuge to remove particulates. To separate IGF-1 from their binding proteins, the samples 
were extracted by combining 25 μl plasma and 100 μl Activation Buffer. They were mixed well, left 
at room temperature for 30 minutes and centrifuged for 5 minutes. 25 μl of supernatant was 
transferred into a microfuge tube and 15 μl of Neutralization Buffer was added and mixed well. 
Then 260 μl of Assay Buffer was added to the neutralized sample for a final volume of 300 μl. The 
samples were diluted to 1:60.  
Reagents for the immunoassay were prepared according to the manufacture’s manual. Antibody-
immobilized beads were prepared by adding 150 μl of each antibody-bead vial and then assay 
buffer was added to reach the final volume of 3.0 ml. Quality control 1 and 2 were reconstituted 
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with 250 ml of deionized water. Wash buffer was prepared by mixing 60 ml of 10X Wash Buffer 
and 540 ml of deionized water. Then IGF-1 standard was prepared: at first Standard #7 and 250 μl 
of deionized water were mixed. Then Standard #6 was prepared by mixing 200 μl of Assay Buffer 
and 100 μl of Standard #7. The Standard #5 was prepared similarly but previously prepared 
Standard #6 was used in this case. The procedure continued with the similar logic to prepare all 
the Standards from #7 to #1. Then the Working Standards were ready. Assay Buffer was used as a 
background (the 0 pg/ml standard). (45) 
A 96-well plate was used. 200 μl of Assay Buffer was added into each well of the plate. The plate 
was sealed and mixed for 10 minutes on a plate shaker at the room temperature (20 – 25 °C). 
Assay Buffer was decanted and removed from all the wells by inverting the plate and tapping it 
onto absorbent paper towels. 25 μl of Standard or Control were added to appropriate wells 
according to the well map. 25 μl of Assay Buffer was added to background and sample wells. Then 
25 μl of Assay Buffer was added to background, standards, and control wells. 25 μl of extracted 
and diluted plasma samples were added to appropriate wells. 25 μl of beads were added to each 
well. The plate was sealed, wrapped with foil and incubated with agitation for 17 hours at 4 °C. 
After the incubation the plate was set on a magnetic plate washer for 60 seconds so that magnetic 
beads were able to settle. The well contents were removed by inverting and tapping the plate. The 
magnetic plate was removed, 200 μl of Wash Buffer was added to each well and the plate was 
shaken for 30 seconds. The magnet plate was attached again. After 60 seconds the well contents 
were removed like during the first wash. The plate washing was repeated 3 times. Then 50 μl of 
Detection Antibodies were added into each well and the plate was sealed, covered with foil and 
incubated with agitation for 1 hour at room temperature, then followed by adding 50 μl of the 
reporter molecule Streptavidin-Phycoerythrin to each well. The plate was sealed, covered with foil 
and incubated with agitation for 30 minutes at room temperature. The well plate was set on a 
magnetic plate and the plate was washed 3 times as described earlier. 100 μl of Sheath Fluid was 
added to all wells. The beads were resuspended on a plate shaker for 5 minutes. Then the plate 
was run on Bioplex-200 instrument with Bio-Plex Manager software (Bio-Rad). The Median 
Fluorescent Intensity data using a 5-parameter logistic method for calculating IGF-1 concentration 
in samples was saved and analyzed. The final concentrations were multiplied by the dilution 
factor. (45) 
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Laboratory analyses of IGFBP-3 
Laboratory analyses of IGFBP-3 were conducted with a similar procedure according to the 
instructions provided by the manufacturer (45, 46). The test kit included necessary fluids that were 
used in the analyses. Standard 7 was prepared by using the Human IGFBP-3 standard. (46) Other 
names of the reagents were similar compared to IGF-1 test kit (45, 46). 
 
Laboratory analyses of maternal CRP and AGP 
Maternal CRP and AGP at enrollment were analyzed from plasma samples by immunoturbidimetry 
on the Cobas Integra 400 system autoanalyzer (F. Hoffmann-La Roche Ltd, Basel, Switzerland) in 
US.  
 
2.5 Statistical analyses 
The data was analyzed using IBM SPSS Statistics version 25. Spearman’s correlation was used for 
numerical variables which were not normally distributed (IGF-1, IGFBP-3, CRP, AGP, height, BMI, 
maternal age, household wealth). Correlation was significant at the 0,05 level (2-tailed) unless 
otherwise specified in further sections. The distributions of IGF-1 and IGFBP-3 concentrations were 
analyzed among different age groups by using independent samples Kruskal-Wallis test. Mann-
Whitney U-test was used when comparing the results between girls and boys at different age groups 
and when comparing the results between dry and rainy season. Kruskal-Wallis test was used when 
association between child plasma IGF-1 concentration and a categorical variable (the site of sample 
collection, source of drinking water, sanitation facility) was analyzed. Similar method was used in 
analyses of plasma IGFBP-3 concentrations and a categorical variable.  
 
2.6 Ethical aspects 
The data and plasma samples were collected as a part of iLiNS-DYAD project. Ethical aspects have 
been considered in TEKES research plan: “The controlled trial was performed according to Good 
Clinical Practice guidelines (ICH-GCP) and it adhered to the principles of Helsinki declaration and 
regulatory guidelines in Malawi. The trial protocol was discussed and approved prior to the onset of 
data collection by ethics committees in Malawi (College of Medicine) and Finland (Pirkanmaa 
 18 
 
Hospital District). All participants were given appropriate information on the studies and they all 
signed an informed consent form before enrolment. Individual identifiers have been removed from 
the study databases and hence the suggested secondary analyses pose no major ethical questions.” 
(43) 
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3. RESULTS 
 
3.1 Study subjects, maternal characteristics and environmental factors  
Mean child ages at sample collection were 6.39 (SD 1.19, n = 519) months, 18.14 (SD 0.34, n = 605) 
months and 30.07 (SD 0.20, n = 581) months. Maternal data at time of enrollment were used in 
the analyses of this study. The maternal characteristics are represented in Table 2. The wealth of 
household was evaluated with an asset index which is based on asset ownership of certain things 
and environmental factors (for example sanitation facilities) (47). Thus, evaluation of household 
wealth was not based on household income. Distributions of the sites of sample collection, 
sources of drinking water and sanitation facilities are represented in Tables 3, 4 and 5, 
respectively.  
 
Table 2. Maternal characteristics and household wealth at enrollment. 
 N Mean ± SD  
Maternal age (years) 686 25.1 ± 6.0 
Maternal height (cm) 686 156 ± 5.6 
Maternal BMI (kg/m2) 685 21.9 ± 2.7 
Household wealth 685 -0.075 ± 0.95 
Maternal CRP (mg/l) 674 8.29 ± 17.0 
Maternal AGP (g/l) 674 0.71 ± 0.25 
N: total number, SD: standard deviation, BMI: body mass index, CRP: C-reactive protein, AGP: 
alpha-1-acid glycoprotein 
 
 
 
Table 3. The distributions of the sites of sample collection. 
 N % 
Lungwena 357 51.4 
Malindi 127 18.3 
Mangochi 204 29.4 
Missing 7 1.0 
N: total number, %: percentage of the study population 
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Table 4. The distributions of the source of drinking water among the households of the study 
population. 
 N %  
Piped water 100 14.4 
Borehole 518 74.6 
Protected well 15 2.2 
Unprotected well 22 3.2 
Lake 35 5.0 
River, pond 3 0.4 
Not specified / missing 1 0.1 
N: total number, %: percent of the study population 
 
 
 
Table 5. The distributions of the sanitation facility among the households of the study 
population. 
 N % 
None 32 4.6 
Regular pit latrine 597 86.0 
Ventilated improved 
pit latrine 54 7.8 
Water closet 10 1.4 
Not specified 1 0.1 
N: total number, %: percentage of the study population 
 
 
 
3.2 IGF-1 and IGFBP-3 concentrations 
Plasma IGF-1 concentrations at ages of 6, 18, and 30 months are shown in Table 6. The distribution 
of IGF-1 concentration was the same across categories of child age (p = 0.097). 
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Table 6. Plasma concentrations of IGF-1 at 6-, 18- and 30-month-old Malawian children. 
Child age 
(months) N 
Mean ± SD 
(ng/ml) 95 % CI 
6 519 13.10 ± 8.23 12.40 - 13.80 
18 605 12.47 ± 7.62 11.87 - 13.07 
30 581 14.54 ± 10.8 13.67 - 15.41 
IGF-1 : insulin-like growth factor 1, N: total number, SD: standard deviation, CI: confidence interval 
 
Plasma IGFBP-3 concentrations at ages of 6, 18, and 30 months are shown in Table 7. The 
distribution of IGFBP-3 concentration was the same across categories of child age (p = 0.347). 
 
Table 7. Plasma concentrations of IGFBP-3 at 6-, 18- and 30-month-old Malawian children. 
Child age 
(months) N 
Mean ± SD 
(ng/ml) 95  % CI 
6 474 2643 ± 808.0 2570 - 2717 
18 584 2676 ± 719.5 2618 - 2734 
30 580 2652 ± 747.1 2592 - 2712 
IGFBP-3: insulin-like growth factor binding protein 3, N: total number, SD: standard deviation, CI: 
confidence interval 
 
 
IGF-1 and IGFBP-3 concentrations among boys and girls 
Mean IGF-1 and IGFBP-3 concentrations among 6-, 18- and 30-month-old boys and girls are shown 
in Table 8. The difference in IGF-1 concentrations between 6-month-old boys and girls was not 
significant (p = 0.574). However, the differences were significant between boys and girls at age of 
18 months (p ≤ 0.001) and at age of 30 months (p ≤ 0.001). IGF-1 concentrations were higher 
among girls than boys at ages of 18 and 30 months though the trend was also similar at age of 6 
months.  
IGFBP-3 concentrations were higher among girls than boys and the difference was statistically 
significant in all age groups (p = 0.03, p ≤ 0.001 and p ≤ 0.001 at ages of 6, 18, and 30 months, 
respectively).  
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Table 8. Plasma concentrations of IGF-1 and IGFBP-3 among boys and girls at 6-, 18- and 30-
month-old Malawian children.  
  IGF-1  IGFBP-3  
Child age 
(months) Sex of child 
Mean ± SD 
(ng/ml) 95 % CI 
Mean ± SD 
(ng/ml) 95 % CI 
6 Boy 12.97 ± 8.67 11.88 - 14.05 2542 ± 748 2441 - 2642 
 Girl 13.10 ± 7.65 12.20 - 14.00 2731 ± 853 2624 - 2837 
18 Boy 11.29 ± 7.19 10.48 - 12.11 2513 ± 646 2437 - 2588 
 Girl 13.52 ± 7.90 12.64 - 14.39 2834 ± 754 2749 - 2919 
30 Boy 12.55 ± 10.16 11.37 - 13.73 2470 ± 688 2391 - 2550 
 Girl 16.36 ± 11.03 15.12 - 17.60 2821 ± 761 2736 - 2907 
IGF-1: insulin-like growth factor 1, IGFBP-3: insulin-like growth factor binding protein 3, SD: 
standard deviation, CI: confidence interval 
 
 
 
3.3 Correlations between maternal characteristics, environmental factors and IGF-
1 concentrations 
Correlations between IGF-1 concentrations and maternal characteristics are shown in Table 9. 
Maternal height and IGF-1 concentrations were associated in all age groups. Maternal body mass 
index (BMI) and maternal AGP concentrations were associated with IGF-1 concentrations at age of 
6 months, wealth of household with IGF-1 at age of 30 months. Maternal age and CRP 
concentrations were not associated with IGF-1 concentrations in any age group.  
 
Table 9. Correlation coefficients between maternal characteristics and IGF-1 concentrations at 6-
, 18- and 30-month-old Malawian children.  
 6 months  18 months  30 months  
 Coefficient P value Coefficient P value Coefficient P value 
Maternal age 0.41 0.345 0.009 0.826 0.040 0.330 
Maternal height 0.150 0.001 0.112 0.005 0.119 0.004 
Maternal BMI 0.123 0.005 0.011 0.787 -0.011 0.784 
Household wealth 0.044 0.316 0.062 0.122 0.134 0.001 
Maternal CRP 0.047 0.284 0.041 0.310 0.038 0.359 
Marernal AGP -0.124 0.005 0.076 0.062 0.032 0.437 
IGF-1: insulin-like growth factor 1, BMI: body mass index, CRP: C-reactive protein, AGP: alpha-1-
acid glycoprotein 
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IGF-1 concentrations during dry season (May to October) and rainy season (November to April) are 
shown in Table 10. IGF-1 concentrations were higher among the samples collected during dry 
season compared to the samples collected during rainy season at ages of 6 and 18 months (p ≤ 
0.001 and p = 0.003, respectively). Though the trend was similar, the differences in IGF-1 
concentrations were not statistically significant between the samples collected during dry season 
and rainy season at age of 30 months (p = 0.062). 
 
Table 10. Plasma concentrations of IGF-1 among 6-, 18- and 30-month-old Malawian children 
whose samples were collected during dry and rainy season.  
Child age 
(months) Season 
Mean ± SD 
(ng/ml) 95 % CI 
6 Dry 14.72 ± 8.81 13.61 - 15.84 
 Rainy 11.71 ± 7.45 10.85 - 12.58 
18 Dry 13.40 ± 8.13 12.49 - 14.31 
 Rainy 11.56 ± 6.99 10.79 - 12.34 
30 Dry 15.53 ± 11.55 14.20 - 16.86 
 Rainy 13.59 ± 9.96 12.46 - 14.72 
IGF-1: insulin-like growth factor 1, SD: standard deviation, CI: confidence interval 
 
IGF-1 concentrations were similar across the site of sample collection and the source of drinking 
water at ages of 6, 18 and 30 months (p = 0.746, p = 0.855 and p = 0.074 for the site of sample 
collection; p = 0.492, p = 0.116 and p = 0.055 for the source of drinking water, respectively).  
IGF-1 concentrations were similar across the sanitation facilities at ages of 6 and 30 months (p = 
0.559 and p = 0.066, respectively) but the difference was statistically significant at age of 18 months 
(p = 0.007). Statistically significant results of pairwise comparison are shown in Table 11. IGF-1 
concentrations were higher among those who have access to water closet compared to those who 
use regular pit latrine, ventilated improved pit latrine or have no sanitation facilities. 
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Table 11. The results of selected comparisons and adjusted significances. IGF-1 concentrations 
were compared across the sanitation facilities among 18-month-old Malawian children. 
Compared sanitation facilities Adjusted significance* 
Regular pit latrine - water closet 0.004 
None - water closet 0.031 
Vent. impr. pit latrine - water closet 0.024 
*Significance values have been adjusted by the Bonferroni correction for multiple tests. Vent. impr. 
pit latrine: ventilated improved pit latrine 
 
3.4 Correlations between maternal characteristics, environmental factors and 
IGFBP-3 concentrations 
Correlations between IGFBP-3 concentrations and maternal characteristics are shown in Table 12. 
There were no association either between IGFBP-3 concentrations and maternal BMI. Maternal 
height was associated with IGFBP-3 concentrations in all age groups. Wealth of household was 
associated with IGFBP-3 concentrations at ages of 6 and 30 months, and maternal AGP was 
negatively associated with IGFBP-3 concentrations at ages of 6 and 18 months. Maternal age and 
CRP were not associated with IGFBP-3 concentrations in any age group.  
 
Table 12. Correlations between maternal characteristics and IGFBP-3 concentrations at 6-, 18- and 
30-month-old Malawian children.  
 6 months  18 months  30 months  
 Coefficient P value Coefficient P value Coefficient P value 
Maternal age 0.058 0.210 -0.008 0.848 0.036 0.386 
Maternal height 0.119 0.010 0.104 0.011 0.118 0.004 
Maternal BMI 0.037 0.426 0.033 0.418 -0.029 0.479 
Household wealth 0.127 0.006 0.052 0.207 0.154 ≤ 0.001 
Maternal CRP -0.047 0.312 -0.014 0.734 -0.004 0.916 
Maternal AGP -0.160 0.001 -0.090 0.030 -0.076 0.069 
IGFBP-3: insulin-like growth factor binding protein 3, BMI: body mass index, CRP: C-reactive 
protein, AGP: alpha-1-acid glycoprotein 
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IGFBP-3 concentrations during dry season and rainy season are shown in Table 13. IGFBP-3 
concentrations at ages of 18 and 30 months were higher among the samples collected during dry 
season compared to rainy season (p ≤ 0.001 and p = 0.023, respectively), but not at age of 6 
months (p = 0.175). 
 
Table 13. Plasma concentrations of IGFBP-3 among 6-, 18- and 30-month-old Malawian children 
whose samples were collected during dry and rainy season. 
Child age 
(months) Season 
Mean ± SD 
(ng/ml) 95 % CI 
6 Dry 2619 ± 587 2538 - 2700 
 Rainy 2663 ± 946 2547 - 2778 
18 Dry 2739 ± 630 2667 - 2811 
 Rainy 2615 ± 793 2526 - 2705 
30 Dry 2685 ± 673 2608 - 2763 
 Rainy 2620 ± 813 2528 - 2712 
IGFBP-3: insulin-like growth factor binding protein 3, SD: standard deviation, CI: confidence 
interval 
 
The differences in IGFBP-3 concentrations across the site of sample collection were statistically 
significant at ages of 6 and 30 months (p = 0.042 and p = 0.017, respectively) but not at age of 18 
months (p = 0.536). Adjusted significances at ages of 6 and 30 months are shown in Table 14. IGFBP-
3 concentrations were higher in the samples collected in Mangochi compared to Lungwena at ages 
of 6 and 30 months. 
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Table 14. The results of comparisons and adjusted significances. IGFBP-3 concentrations were 
compared across the sites of sample collection among 6- and 30-month-old Malawian children. 
Compared sites Child age (months) Adjusted significance* 
Lungwena - Mangochi 6 0.042 
 30 0.014 
Lungwena - Malindi 6 0.519 
 30 1.000 
Malindi - Mangochi 6 1.000 
 30 0.265 
*Significance values have been adjusted by the Bonferroni correction for multiple tests. 
 
The differences in IGFBP-3 concentration across the source of drinking water were statistically 
significant at ages of 6 and 30 months (p = 0.018 and p = 0.005, respectively) but not at age of 18 
months (p = 0.373). In pairwise comparison the adjusted significances were not statistically 
significant at age of 6 months. The only statistically significant difference was that IGF-1 
concentrations were higher among those who have access to piped water compared to those who 
have access to borehole at age of 30 months. Adjusted significances are shown in Table 15. If 
adjusted significance was 1.000 at both ages (6 and 30 months), those pairs are not presented. 
 
Table 15. The results of selected comparisons and adjusted significances. IGFBP-3 concentrations 
were compared across the sources of drinking water among 6- and 30-month-old Malawian 
children. 
Compared sources of drinking water Child age (months) Adjusted significance* 
Protected well - piped water 6 0.403 
 30 0.074 
Protected well - lake 6 0.489 
 30 1.000 
Borehole - piped water 6 0.158 
 30 0.004 
Unprotected well - piped water 6 1.000 
 30 0.377 
*Significance values have been adjusted by the Bonferroni correction for multiple tests. 
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The distribution of IGFBP-3 concentration was the same across the sanitation facilities at ages of 6, 
18 and 30 months (p = 0.922, p = 0.612 and p = 0.925, respectively). 
 
3.5 Correlations between IGF-1 and IGFBP-3 concentrations 
The correlations between IGF-1 and IGFBP-3 concentrations at 6-, 18- and 30-month-old Malawian 
children are shown in Table 16. Child plasma IGF-1 were associated with IGFBP-3 concentrations in 
all age groups.  
 
Table 16. Correlation coefficients between plasma IGF-1 and IGFBP-3 concentrations at 6-, 18- and 
30-month-old Malawian children.  
 6 months  18 months  30 months  
 Coefficient P value Coefficient P value Coefficient P value 
Correlation 0.537 ≤ 0,001 0.570 ≤ 0,001 0.588 ≤ 0,001 
IGF-1: insulin-like growth factor 1, IGFBP-3: IGF binding protein 3 
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4. DISCUSSION 
4.1 Main findings  
This study investigated the distribution of IGF-1 and IGFBP-3 concentrations among 6-, 18- and 30-
month-old Malawian children. The study also assessed if maternal/child characteristics and 
environmental factors affect IGF-1 and IGFBP-3 concentrations. There were no significant 
differences in IGF-1 and IGFBP-3 concentrations among 6-, 18- and 30-month-old Malawian 
children. However, we found that IGF-1 and IGFBP-3 concentrations were higher among girls 
compared to boys among almost all age groups except IGF-1 at 6-month-old infants. Higher 
maternal height was associated with higher child IGF-1 and IGFBP-3 concentrations in all age 
groups. The higher the household wealth, the higher the IGF-1 concentrations at child age of 30 
months and the higher IGFBP-3 concentrations at child ages 6 and 30 months. The higher the 
mother’s AGP concentration the lower IGF-1 concentration at age of 6 months. IGF-1 and IGFBP-3 
concentrations were higher among the samples collected during dry season compared to the 
samples collected during rainy season.  IGF-1 and IGFBP-3 concentrations were strongly correlated 
with each other among all age groups. IGF-1 concentrations at age of 18 months were higher 
among those who have access to water closet compared to those who have access to some other 
sanitation facility.  IGFBP-3 concentrations at age of 30 months were higher among those who 
have access to piped water compared to those who have access to borehole. IGFBP-3 
concentrations were different between the samples collected in Mangochi and Lungwena among 
6- and 30-month-old children.   
 
4.2 Limitations  
IGF-1 and IGFBP-3 concentrations were measured only three times and the follow-up time was 
relatively short. Thus, it is not possible to get accurate information about IGF-1 and IGFBP-3 
concentrations among other age groups. It should be also noticed that there are many factors that 
affect IGF-1 and IGFBP-3 concentrations and only some of them were included in this study. 
Environmental factors were relatively similar in the study population. Thus, statistically significant 
differences among environmental factors were found in a few groups.    
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4.3 Distribution of IGF-1 concentrations 
Previous studies have found that IGF-1 concentrations increase during childhood (31, 34-36, 39). 
Some other studies have found that IGF-1 concentrations are relatively high at birth, decrease 
during the first months of life and then increase gradually during childhood (33, 38). The 
distribution of IGF-1 concentration was the same across categories of child age in this study. Thus, 
increase in IGF-1 concentrations was not statistically significant and increase in IGF-1 
concentrations during childhood was not observed in our study. It is possible that the study 
population suffers from malnutrition which negatively affects growth and prevents normal 
increase in IGF-1 concentrations.  
Exclusive breastfeeding is recommended during the first 6 months of life (48). If mothers have 
adhered to the recommendation it can be assumed that at 6 months of age children get majority 
of daily energy demand from breast milk and the role of other nutrition is less significant. This 
situation is different at ages of 18 and 30 months: nutritional status depends more on dairy 
products, amount of carbohydrates and quality of fatty acids (13). In addition, important time for 
linear growth is from 6 to 24 months of age. Energy demand is high during that time which 
increases risk of stunting. (8) The study population is from low-income settings where amount and 
quality of nutrition might be suboptimal. Since nutritional status affects IGF-1 concentrations (16, 
49), poor nutritional status combined with important linear growth phase might prevent increase 
in IGF-1 concentrations between ages 6 and 30 months.  
EED might also explain why IGF-1 concentrations did not increase significantly from 6 to 30 
months. EED is more common in low- and middle-income countries (25), such as in Malawi (50). 
EED deteriorates nutrient absorption which might lead to energy deficiency and cause stunting 
(25). Among undernourished children IGF-1 concentrations are decreased (51). In addition, 
stunting and undernutrition are common in sub-Saharan Africa (4) which might be one explanation 
for IGF-1 concentrations in this study.  
Mean IGF-1 concentrations in our study were lower than in those studies carried out in higher-
income countries (33-35, 39, 40) where likelihoods of stunting and EED are lower (8) than in 
Malawi. Kouanda et al. had study population from Burkina Faso. In their study IGF-1 
concentrations decreased from birth to 24 months of age and increased after that. (38) Burkina 
Faso and Malawi are both low-recourse settings which may play a role for stunting, nutrition, EED 
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and IGF-1 concentrations. On the other hand, IGF-1 concentrations among the study population in 
Burkina Faso were higher than IGF-1 concentrations in our study even though economic and 
environmental factors might have similarities between those countries. Also ethnicity affects IGF-1 
concentration (41), possibly even when comparing the results of two African countries.  
 It should be also taken into account that different laboratory methods were used in the studies 
listed in Table 1. For example chemiluminescent assay was used in some studies (33, 34, 40) but 
none of the studies used EMD Millipore Human IGF-1 laboratory test kit. ELISA method was also 
used in a couple of studies (19, 31). Kouanda et al. used filter paper, radioimmunoassay and 
chromatography (38). Thus, comparing IGF-1 concentrations among different studies is not 
straightforward. To get comparable results the same method or similar test kits should be used.  
IGF-1 concentrations were higher among the girls compared to boys. Our results are consistent 
with previous studies (31, 41). The difference between sexes is more significant during puberty 
(35, 40) but should be taken into account in infancy and childhood if IGF-1 results are used for 
example in some diagnostic procedures.   
IGF-1 concentrations were higher among the samples collected during dry season compared to 
rainy season among all age groups. The difference was significant at ages of 6 and 18 months. It 
might be possible that amount and quality of nutrition is different during dry and rainy season 
which affects nutritional status and IGF-1 concentrations. Another possible reason is that children 
are more prone to have infections during rainy season which decreases IGF-1 concentrations.  
 
4.4 Distribution of IGFBP-3 concentrations 
The differences in mean IGFBP-3 concentrations were not statistically significant among three 
different age groups in this study. In some previous studies it has been noticed that IGFBP-3 levels 
increase from early childhood to puberty (36, 41). The increase in IGFBP-3 concentrations was not 
linear in this study. The differences in mean IGFBP-3 concentration were statistically significant 
between girls and boys among all age groups. Our results are inconsistent with a previous study 
conducted in Turkey. Yüksel et al. found no significant differences in IGFBP-3 concentrations 
between girls and boys. (31) Ethnicity affects IGFBP-3 concentrations (33) which might explain the 
inconsistency. Chaler et al. suggest that different reference values of IGF-1 and IGFBP-3 should be 
used for people with different ethnic background. In their study it was observed that numerical 
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values of IGF-1 and IGFBP-3 concentrations were different even when compared to another study 
with similar laboratory method but different ethnic study group. (41) 
IGFBP-3 concentrations at ages of 18 and 30 months were higher among the samples collected 
during dry season compared to rainy season. It could be assumed that seasonal variations among 
IGF-1 and IGFBP-3 concentrations are dependent on each other. Thus, similar factors such as 
nutrition and infections might affect both biomarkers.  
 
4.5 Correlations between IGF-1 and IGFBP-3 
IGF-1 and IGFBP-3 concentrations were associated with each other in this study population. The 
finding can be explained by the biological functions: IGFBP-3 is the carrier protein of IGF-1 (11). On 
the other hand, association is moderate but not high. There might be several reasons for that: 
affinity of IGF-1 and IGFBP-3, other binding proteins of IGF-1 and inaccuracies of laboratory 
analyses might affect the concentrations. Yüksel et al. found weak correlations between IGF-1 and 
IGFBP-3 concentrations in some age groups among 0 – 6 years old Turkish children (31) but 
specific results about correlations were not defined in the paper.  
 
4.6 Association between maternal characteristics, environmental factors and IGF-
1, IGFBP-3 concentrations 
It has been suggested that maternal inflammatory process could be the link between prenatal and 
antenatal stunting (8). Thus, maternal inflammatory process might affect child IGF-1 
concentration. Our study did not find association between maternal CRP and child plasma IGF-1 
concentration in any age group. Maternal CRP was measured at enrollment during pregnancy. CRP 
is an acute phase protein which reacts relatively fast (5) so the concentrations might vary 
depending on the day of sample collection. Measuring maternal CRP might not be a good indicator 
of long-term inflammatory processes which might have more significant and longer-lasting effects 
on child growth and IGF-1 concentrations. However, weak negative association was found 
between maternal AGP and child IGF-1 at age of 6 months. AGP concentrations change slowly 
compared to CRP (5) which might indicate that maternal inflammatory process has been more 
persistent and negatively affected child growth and IGF-1 concentrations.  
The association between maternal height and child plasma IGF-1 concentration was noticed in this 
study. If maternal height is above the average it might be possible that also child’s height is above 
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the average.  Since IGF-1 is an important regulator of child growth (9) and IGF-1 concentrations are 
higher among the children whose height is above the average (52), the association between 
maternal height and child IGF-1 concentration can be understood. The association between 
maternal BMI and child plasma IGF-1 concentration was not significant. It should be taken into 
account that average BMI was 21.9 (SD 2.7) which is normal. The results might have been different 
if there were more underweight women whose children might be in higher risk of stunting. IGF-1 
concentrations would be lower in that case.  
Wealth of household might lead to better chances to get adequate nutrition for children. The 
educational level is usually higher among people living in wealthier households (8) which might be 
associated with better knowledge about nutrition and hygiene. Thus, advanced environmental 
factors such as clean drinking water and proper sanitation facilities might be associated with 
better child growth and higher IGF-1 concentrations. In this study population IGF-1 concentrations 
were associated with the wealth of household at age of 30 months. If nutrition and hygiene are 
better among wealthier households that might be seen in IGF-1 concentrations only when children 
are old enough and they have been exposed to environmental factors long enough.  
The site of sample collection and the source of drinking water did not affect IGF-1 concentrations 
but these environmental factors affected IGFBP-3 concentrations in a few groups. IGFBP-3 
concentrations from the samples collected in Mangochi were higher compared to Lungwena when 
the concentrations were compared at ages of 6 and 30 months. It is not clear why the results were 
different between these two sites and two age groups. All three sites are rural so it could be 
assumed that the living environments are similar. It is also assumed that maternal enrollment in 
the study was similar among the three sites.  
The source of drinking water affected the distribution of IGFBP-3 concentration at age of 30 
months when borehole and piped water were compared. Some differences were also seen when 
piped water and protected or unprotected well were compared but in these cases the differences 
were not statistically significant. It might be possible that access to piped water is associated with 
better hygiene, fewer infections, better growth and higher IGFBP-3 concentrations compared to 
those who do not have access to piped water.  
The difference in the distribution of IGF-1 concentration across the sanitation facilities was 
statistically significant at age of 18 months. In pairwise comparison the other sanitation facility was 
water closet when the difference was statistically significant. Thus, it could be assumed that access 
 33 
 
to water closet has similar effects as access to piped water. These factors might explain higher IGF-
1 concentrations among those who have access to water closet. On the other hand, access to water 
closet did not affect IGFBP-3 concentrations in any age group. 
In conclusion, IGF-1 and IGFBP-3 concentrations have some similar patterns among rural Malawian 
children compared to previous studies but numerical values of concentrations vary between 
different study groups and laboratory methods. Comparing the results of different research groups 
is not straightforward when the methods used are different. It should be also noticed that ethnic 
backgrounds of the populations are probably different which may play a role in the results of IGF-1 
and IGFBP-3 concentrations. Thus, the reference values should be measured among similar 
population and with similar laboratory method to get comparable results which could be used for 
example in some diagnostic procedures. In the future, IGF-1 could be one marker in monitoring 
child’s risk of stunting and EED in low- and middle-income countries. The method of measuring 
IGF-1 should be practical and feasible in low-recourse settings. The role of maternal and 
environmental factors should be taken into account when evaluating the results.  
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